Steve Dickman
CEO, CBT Advisors CBT Advisors CEO Steve Dickman has worked in consulting and venture capital for more than twenty-five years.
About this speaker
CBT Advisors CEO Steve Dickman has worked in consulting and venture capital for more than twenty-five years. He founded CBT Advisors in 2003 and has worked on storytelling and strategy with more than four hundred private biotechnology and life sciences and medical device clients.
Much of the firm’s work focuses on drafting business sections for NASDAQ IPOs. Ninety-five of the firm’s clients have gone public including Rapport Therapeutics, CRISPR Therapeutics, Argenx, Legend Biotech, Inspire Medical and Dicerna. Other S-1 clients have been acquired including Karuna Therapeutics ($14 billion in 2023); Forty-Seven ($4.9 billion in 2020) and Translate Bio ($3.2 billion in 2021).
Previously, Steve spent four years as a venture capitalist with TVM Capital, where his investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio, which went public on Nasdaq (BLUE) in 2013 and reached a peak valuation above $4.4 billion in 2019. Mr. Dickman holds a BA in Biochemistry from Princeton University.
He was a reporter with Nature, Science and The Economist before entering the life sciences industry.
